[
  {
    "ts": null,
    "headline": "Pfizer Pipeline Progress And Partnerships Tested Against Depressed Valuation",
    "summary": "Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced hemophilia patients. Partnered antifungal Cresemba reached sales in Asia Pacific that triggered a milestone payment to Pfizer. Pfizer joined the BaseLaunch biotech incubator as a partner to work with early stage drug developers. Pfizer enters this news cycle with its shares at $27.05 and a mixed return profile, with a 13.6% gain over the past year, a 25.9% decline over three...",
    "url": "https://finnhub.io/api/news?id=e719aafeadb010403de777c4c04b92144f930b46f719f50f712bf092edb482f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770754168,
      "headline": "Pfizer Pipeline Progress And Partnerships Tested Against Depressed Valuation",
      "id": 139036363,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced hemophilia patients. Partnered antifungal Cresemba reached sales in Asia Pacific that triggered a milestone payment to Pfizer. Pfizer joined the BaseLaunch biotech incubator as a partner to work with early stage drug developers. Pfizer enters this news cycle with its shares at $27.05 and a mixed return profile, with a 13.6% gain over the past year, a 25.9% decline over three...",
      "url": "https://finnhub.io/api/news?id=e719aafeadb010403de777c4c04b92144f930b46f719f50f712bf092edb482f0"
    }
  },
  {
    "ts": null,
    "headline": "Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?",
    "summary": "BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.",
    "url": "https://finnhub.io/api/news?id=70152b51779bd9a533304b4d0ef9fe5769184f1cd54b14f1fbce71453ee519b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770739560,
      "headline": "Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?",
      "id": 139033468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.",
      "url": "https://finnhub.io/api/news?id=70152b51779bd9a533304b4d0ef9fe5769184f1cd54b14f1fbce71453ee519b2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Announces FDA’s Grant of Priority Review for HYMPAVZI® (marstacimab) sBLA",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best healthcare stocks under $50 to invest in. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of hemophilia A […]",
    "url": "https://finnhub.io/api/news?id=9af887922c3efa4750546dba04ef93ca0375bb8b3c02655805d0817b7f5e7c8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770737976,
      "headline": "Pfizer Inc. (PFE) Announces FDA’s Grant of Priority Review for HYMPAVZI® (marstacimab) sBLA",
      "id": 139031976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best healthcare stocks under $50 to invest in. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of hemophilia A […]",
      "url": "https://finnhub.io/api/news?id=9af887922c3efa4750546dba04ef93ca0375bb8b3c02655805d0817b7f5e7c8b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=9287bea79ba37a9a29a628145e3f4c75f146dab3b4293c9c30330a95e885adce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770732004,
      "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 139031977,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=9287bea79ba37a9a29a628145e3f4c75f146dab3b4293c9c30330a95e885adce"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Becomes Newest Partner Added to BaseLaunch's Biotech Venture Incubator",
    "summary": "BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the pharmaceutical giant Pfizer has joined the Basel-based incubator, bringing the total number of leading pharma company partners to seven.",
    "url": "https://finnhub.io/api/news?id=7defa23931a286b0f839b6a4667e70834f7daa32f92d44ea40720ef462f675bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770728340,
      "headline": "Pfizer Becomes Newest Partner Added to BaseLaunch's Biotech Venture Incubator",
      "id": 139029638,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the pharmaceutical giant Pfizer has joined the Basel-based incubator, bringing the total number of leading pharma company partners to seven.",
      "url": "https://finnhub.io/api/news?id=7defa23931a286b0f839b6a4667e70834f7daa32f92d44ea40720ef462f675bb"
    }
  },
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call",
    "summary": "Pfizer closed the fourth quarter with revenue ahead of Wall Street expectations, but the market reacted negatively due to a combination of year-over-year sales decline and shrinking operating margins. Management explained that the drop in COVID-19 product demand weighed heavily on overall results, while non-COVID products delivered solid operational growth. CEO Albert Bourla cited the impact of a “narrow recommendation for vaccines in the US” as a driver behind lower COVID product sales and high",
    "url": "https://finnhub.io/api/news?id=521783e538b6849838451715cd48a54f5c064a15fec993e0dfbda098fbc56d07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770701859,
      "headline": "5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call",
      "id": 139028438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer closed the fourth quarter with revenue ahead of Wall Street expectations, but the market reacted negatively due to a combination of year-over-year sales decline and shrinking operating margins. Management explained that the drop in COVID-19 product demand weighed heavily on overall results, while non-COVID products delivered solid operational growth. CEO Albert Bourla cited the impact of a “narrow recommendation for vaccines in the US” as a driver behind lower COVID product sales and high",
      "url": "https://finnhub.io/api/news?id=521783e538b6849838451715cd48a54f5c064a15fec993e0dfbda098fbc56d07"
    }
  }
]